Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2189 | Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki | 1.00 |
| drug1729 | High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki | 1.00 |
| drug2320 | Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3089 | Probiorinse Wiki | 1.00 |
| drug2977 | Placebo on a 0- and 28-day schedule Wiki | 0.71 |
| drug3510 | Saline solution Wiki | 0.71 |
| drug2321 | Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
| drug2190 | Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
| drug1730 | High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D003141 | Communicable Diseases NIH | 0.07 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This study is a randomized, double-blinded, and placebo-controlled phase Ia/IIa clinical trial of the Inactivated SARS-CoV-2 Vaccine to evaluate the safety and immunogenicity of the vaccine in healthy people aged 18~59 Years.
Description: Occurence of adverse reactions/events after vaccination
Measure: Adverse reactions/events rate Time: 7 days after vaccinationDescription: Occurence of adverse reactions/events after vaccination
Measure: Adverse reactions/events rate Time: 28 days after vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Occurence of Serious adverse events after vaccination
Measure: Serious adverse events Time: 12 months after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,14
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 14 days after the second vaccinationDescription: Seroconversion rate of neutralizing antibodies against SARS-CoV-2 in serum for the Phase Ia immunization schedule of day 0,28
Measure: Seroconversion rate of Neutralizing antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Seroconversion rate of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Seroconversion rate of IgG antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,14
Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,14
Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,14
Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,14
Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase Ia immunization schedule of day 0,28
Measure: Level of IgM antibodies against SARS-CoV-2 Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of IgM antibodies against SARS-CoV-2 tested by ELISA in serum for the Phase IIa immunization schedule of day 0,28
Measure: Level of IgM antibodies against SARS-CoV-2 Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase Ia immunization schedule of day 0,28
Measure: Level of anti-N protein antibodies Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Level of anti-N protein antibodies for the Phase IIa immunization schedule of day 0,28
Measure: Level of anti-N protein antibodies Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase Ia immunization schedules
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase Ia (both schedules) Time: 3, 6, 9 and 12 months after the second vaccinationDescription: Level of neutralizing antibodies against SARS-CoV-2 in serum for both the Phase IIa immunization schedules
Measure: Level of Neutralizing antibodies against SARS-CoV-2 Phase IIa (both schedules) Time: 6 and 12 months after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase Ia immunization schedules
Measure: Level of IgG antibodies against SARS-CoV-2 Phase Ia (both schedules) Time: 3, 6, 9 and 12 months after the second vaccinationDescription: Level of IgG antibodies against SARS-CoV-2 tested by ELISA in serum for both the Phase IIa immunization schedules
Measure: Level of IgG antibodies against SARS-CoV-2 Phase IIa (both schedules) Time: 6 and 12 months after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,14
Measure: Cellular immune responses Phase Ia (Day 0, 14 schedule) Time: 7, 14 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,14
Measure: Cellular immune responses Phase IIa (Day 0, 14 schedule) Time: 14 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase Ia immunization schedule of day 0,28
Measure: Cellular immune responses Phase Ia (Day 0, 28 schedule) Time: 7 and 28 days after the second vaccinationDescription: Cellular immune responses (CD4+, CD8+, Th1, Th2, IFN-γ, TNFα, IL-2, IL-6) will be measured for the Phase IIa immunization schedule of day 0,28
Measure: Cellular immune responses Phase IIa (Day 0, 28 schedule) Time: 28 days after the second vaccinationAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports